[Assessment of the cardiotoxicity of recombinant human endostatin using myocardial biochemical markers in cancer patients].
OBJECTIVE
To evaluate the value of the myocardial biochemical markers including creatine kinase MB isoenzyme (CK-MB), cardiac isoform of Tropnin-T (cTnT) and N-termimal pro-brain natriuretic peptide (NT-proBNP) and electrocardiogram (ECG) in monitoring the cardiotoxicity of recombinant human endostatin (rh-endostatin) in cancer patients.


METHODS
Forty cancer patients were divided into two groups and received rh-endostatin in addition to chemotherapy (group A, n=24) or chemotherapy only (Group B, n=24). Serum CK-MB, cTnT levels and plasma NT-proBNP levels were measured and the ECG was recorded in all the patients before and after each of the two therapy cycles.


RESULTS
In group A, serum CK-MB, cTnT and plasma NT-proBNP levels were significantly increased after the treatment in comparison with the baseline levels (P<0.05), but such increment was not observed in group B (P>0.05). With comparable baseline levels of CK-MB, cTnT and NT-proBNP before the treatment (P>0.05), patients in group A showed significantly higher levels of the indices than those in group B after each therapy cycle (P<0.05). Increased ECG abnormality were observed after rh-endostatin treatment in Group A (P<0.05) at a rate significantly higher than that of Group B after the second treatment cycle (P<0.05).


CONCLUSIONS
Rh-endostatin has definite cardiotoxicity, and detection of the myocardial biochemical markers of CK-MB, cTnT and NT-proBNP may help predict the occurrence of cardiotoxicity.
Qin
Jing
J
Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. qinjing_abc @yahoo.com.cn
Zhang
Peng-Hai
PH
Qian
Xin-Yu
XY
Kang
Shi-Jun
SJ
Luo
Rong-Cheng
RC
Wang
Yue-Gang
YG
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000188:drug therapy; D052279:Creatine Kinase, MB Form / Q000097:blood; D043169:Endostatins / Q000009:adverse effects / Q000235:genetics / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood; D010051:Ovarian Neoplasms / Q000097:blood / Q000188:drug therapy; D010446:Peptide Fragments / Q000097:blood; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D018570:Risk Assessment; D020107:Troponin T / Q000097:blood
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D043169:Endostatins; D010446:Peptide Fragments; D011994:Recombinant Proteins; D020107:Troponin T; C109794:pro-brain natriuretic peptide (1-76); D020097:Natriuretic Peptide, Brain; D052279:Creatine Kinase, MB Form